Kinetic fingerprints differentiate anti-Aβ therapies
S. Linse, T. Scheidt, K. Bernfur, M. Vendruscolo, C. M. Dobson, S. I. Cohen, E. Sileikis, M. Lundquist, F. Qian, T. O'Malley, T. Bussiere, P. H. Weinreb, C. K. Xu, G. Meisl, S. Devenish, , O. Hansson
This study uses kinetic analysis and binding measurements to compare four anti-Aβ antibodies, showing aducanumab uniquely reduces Aβ oligomer flux.
bioRxiv · Feb 27, 2020 · PreprintBiophysics